Laboratoires Théa , one of the leading independent European pharmaceutical groups in ophthalmology, have acquired seven branded ophthalmic products from Akorn, Inc including: Zioptan, AcellFX, Betimol, Cosopt, Cosopt PF, AzaSite and Akten. This move expands Théa’s presence into the US eye care industry.
“We are thrilled to expand our presence in the U.S. eye care community with a portfolio of products that are widely recognized and frequently used because they make a difference in patients’ lives,” said Susan Benton, Théa’s General Manager, Head of U.S. “As we introduce additional product lines and bring new innovations to market through our dedicated research and development programs, we are looking forward to engaging with stakeholders to expand our leadership presence on a global scale.”
Théa hope to bring innovative products for the US market in areas which are currently unmet. It is expected that they will file its first New Drug Application with the FDA in the first quarter of 2022 for a version of the glaucoma treatment latanoprost.
In the last quarter of 2022, Théa are planning to launch a new line of branded OTC evidenced-based dry-eye drops and eyelid hygiene products through Similasan Corporation; the leading global maker of eye drops.
James Pickering is our Managing Director and an eye care recruitment expert who has developed an extensive client base and candidate network. He regularly writes articles about industry developments and has received numerous recommendations from industry leaders. You can also connect with James on LinkedIn to stay up to date on the latest eye care news.